metricas
covid
Buscar en
Actas Urológicas Españolas (English Edition)
Toda la web
Inicio Actas Urológicas Españolas (English Edition) Chemotherapy plus estramustine for management of castration-resistant prostate c...
Journal Information
Vol. 38. Issue 3.
Pages 184-191 (April 2014)
Share
Share
Download PDF
More article options
Visits
475
Vol. 38. Issue 3.
Pages 184-191 (April 2014)
Original article
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: Meta-analysis of randomized controlled trials
Quimioterapia con estramustina en el manejo del cáncer de próstata resistente a la castración: metaanálisis de ensayos controlados aleatorizados
Visits
475
C. Zhang, T. Jing, F. Wang, X. Gao, C. Xu, Y. Sun
Corresponding author
sunyh@medmail.com.cn

Corresponding author.
Department of Urology, Changhai Hospital, Second Military Medical University, Shanghai, China
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (4)
Show moreShow less
Tables (2)
Table 1. Characteristics and quality of the included trials.
Table 2. Meta-analysis of grades 3–4 toxicity.
Show moreShow less
Abstract
Objective

Estramustine, an agent with both hormonal and non-hormonal effects in men, is supposed to be effective in treating castration-resistant prostate cancer. However, previous studies have reported conflicting results. We conducted this meta-analysis to evaluate the efficacy and toxicity of additional estramustine to chemotherapy.

Methods

Data sources including PubMed, Medline, EMBASE, and Cochrane Controlled Trials Register were searched to identify potentially relevant randomized controlled trials. Prostate specific antigen (PSA) response, overall survival, and grades 3–4 toxicity were analyzed.

Results

Seven randomized controlled trials, a total of 839 patients, were enrolled. The pooled odds ratio for PSA response was 3.02 (95% CI=1.69–5.39, p=.0002); the pooled hazard ratio for overall survival was .95 (95% CI=.80–1.14, p=.58); the pooled odds ratio for nausea/vomiting and cardiovascular toxicity were 3.90 (95% CI=1.05–14.45, p=.04) and 2.22 (95% CI=1.15–4.30, p=.02). No significant difference was detected for neutropenia, anemia, thrombocytopenia, diarrhea, fatigue, or neuropathy (p>.05).

Conclusions

According to this meta-analysis, chemotherapy with additional estramustine increased the PSA response rate. However, it increased the risk of grade 3 or 4 adverse effects such as nausea/vomiting and cardiovascular events, and the overall survival was not improved for castration-resistant prostate cancer patients.

Keywords:
Prostate cancer
Estramustine
Chemotherapy
Meta-analysis
Resumen
Objetivo

La estramustina, un agente con efectos tanto hormonales como no hormonales en los hombres, se supone que es eficaz en el tratamiento de cáncer de próstata resistente a la castración. Sin embargo, estudios previos han notificado resultados contradictorios. Hemos llevado a cabo este metaanálisis para evaluar la eficacia y la toxicidad de estramustina adicional a la quimioterapia.

Métodos

Se realizaron búsquedas en las bases de datos, incluyendo PubMed, Medline, EMBASE y Cochrane Controlled Trials Register, para identificar los ensayos controlados aleatorizados potencialmente relevantes. Se analizaron la respuesta del antígeno prostático específico (PSA), la supervivencia global y la toxicidad de grado 3 a 4.

Resultados

Siete ensayos controlados aleatorizados, un total de 839 pacientes, fueron incluidos. La odds ratio combinada para la respuesta de PSA fue de 3,02 (IC 95%=1,69-5,39, p=0,0002); el cociente de riesgos instantáneos agrupado de supervivencia global fue de 0,95 (IC 95%=0,80-1,14, p=0,58); la odds ratio combinada para náuseas/vómitos y toxicidad cardiovascular fue de 3,90 (IC 95%=1,05-14,45, p=0,04) y 2,22 (IC 95%=1,15-4,30, p=0,02). No se detectó ninguna diferencia significativa para neutropenia, anemia, trombocitopenia, diarrea, fatiga o neuropatía (p>0,05).

Conclusiones

Según este metaanálisis la quimioterapia con estramustina adicional aumentaba la tasa de respuesta del PSA. Sin embargo, aumentaba el riesgo de efectos adversos de grado 3 o 4 como náuseas/vómitos y los episodios cardiovasculares, y la supervivencia global no mejoró en los pacientes con cáncer de próstata resistente a la castración.

Palabras clave:
Cáncer de próstata
Estramustina
Quimioterapia
Metaanálisis

Article

These are the options to access the full texts of the publication Actas Urológicas Españolas (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Actas Urológicas Españolas (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos